|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | American College of Radiology Imaging Network |
|---|---|
| Collaborator: |
National Cancer Institute (NCI) |
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00008346 |
Purpose
RATIONALE: Screening tests may help doctors detect cancer cells early and plan more effective treatment for cancer. It is not yet known which type of mammography is more effective in detecting breast cancer.
PURPOSE: Screening and diagnostic trial to compare the effectiveness of two types of mammography in detecting breast cancer in women.
| Condition | Intervention |
|---|---|
|
Breast Cancer |
Procedure: breast imaging study Procedure: comparison of screening methods Procedure: radiomammography |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Screening |
| Official Title: | Digital VS. Screen-Film Mammography |
| Study Start Date: | October 2001 |
OBJECTIVES:
OUTLINE: This is a randomized, multicenter study. Participants with postitive screening results are stratified according to age (under 50 vs 50-59 vs 60-70 vs over 70). Participants are randomized to one of two treatment arms.
Quality of life is assessed before the screening mammogram in the first 800 women enrolled. In an additional 1,200 participants (600 with positive screening results and 600 with negative screening results), quality of life is assessed shortly after the screening mammogram and at 1 year.
Participants are followed at 1 year with a repeat screen-film or digital mammogram.
PROJECTED ACCRUAL: A total of 49,500 participants (24,750 per arm) will be accrued for this study within 18 months.
Eligibility| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
No prior breast cancer treated with lumpectomy
Hormone receptor status:
PATIENT CHARACTERISTICS:
Age:
Sex:
Menopausal status:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Contacts and Locations
Show 32 Study Locations| Study Chair: | Etta Pisano, MD | UNC Lineberger Comprehensive Cancer Center |
More Information
| ClinicalTrials.gov Identifier: | NCT00008346 History of Changes |
| Other Study ID Numbers: | CDR0000068399, ACRIN-6652 |
| Study First Received: | January 6, 2001 |
| Last Updated: | April 26, 2011 |
| Health Authority: | United States: Federal Government |
|
breast cancer |
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |